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Abstract 
Among tumors of the central nervous system, gliomas are the most prevalent and are 
associated with the poorest prognosis.  Overall survival rates are low, and combined radio- 
and chemo-therapy provides only marginal benefit; thus it is essential to develop novel 
methods to treat patients with these aggressive tumors.  One promising new area of research 
focuses upon epigenetics, the regulation of genetic expression without modifying the DNA 
base-pair sequence.  Epigenetic mechanisms, such as histone acetylation, methylation, and 
cytosine methylation, have been shown to modulate tumor-suppressor genes in non-
transformed cells. We hypothesized that epigenetic mechanisms contribute to the transformed 
phenotype of gliomas by targeting critical tumor suppressor genes.  Our preliminary research 
showed that low doses (1 - 3 µM) of the histone deacetylase inhibitor HDAC-42 led glioma cell 
lines to undergo cell cycle arrest and apoptosis in a dose dependent fashion.  Similar 
concentrations of HDAC-42 sensitized glioma cell lines to apoptosis induced by standard 
chemotherapeutic drugs (cisplatin, temozolomide).  The diminished apoptotic threshold 
induced by HDAC-42 correlated with decreased sphingosine kinase-1 (SK1) activity, an 
important enzyme promoting survival in GBM tumors.  Despite this promising result, the 
apoptotic effect was modest in several glioma cell lines, which led us to examine the 
importance of other enzymes that contribute towards tumor suppressor gene silencing.  
Recent work has demonstrated that HDAC enzymes associate with repressive SWI/SNF 
complexes containing other co-repressive elements to silence tumor suppressor genes.  
Among the epigenetic enzymes implicated in tumor-suppressor silencing is the protein arginine 
methyl transferase-5 (PRMT5), an enzyme that methylates histones H3 (H3R4) and H4 
(H4R8) that localize to promoter regions of specific genes.  Chromatin immunoprecipitation 
(ChIP) experiments have shown that PRMT5 directly targets the ST7 promoter, a known tumor 
suppressor gene.  Western blot analysis of protein lysates isolated from 6 glioma cell lines has 
shown that PRMT5 is overexpressed, a finding that we have found to be critical for cellular 
transformation.  Western blots have shown that ST7 not expressed in glioma lines but is 
abundantly expressed in non-transformed cells (B cells and fibroblasts).  Through sequence-
specific RNA interference, we are presently targeting PRMT5 expression and examining ST7 
expression.  These experiments will allow us to determine if re-expression of ST7 correlates 
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with restoration of features associated with control of cell growth and survival. Experimental 
therapeutic strategies to target multiple co-repressor enzyme activities are discussed.  
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Introduction 
Gliomas are the most common primary brain tumor in adults (LeFranc, 2005).  Although less 
than 2% of the new tumor cases in the United States annually are primary brain tumors, 
(Chamberlain) this relatively small incidence leads to disproportionate amount of mortality.  
The most prevalent form of glioma, glioblastoma multiforme (GBM), is also the most malignant 
(Collins, 2004).   
 
Glial tumors form from astrocyte cells in the brain.  Normal astrocytes assist neural function in 
several capacities, including the release of glucose to the extracellular space, the uptake of 
neurotransmitters, and the stimulation of oligodendrocytes to secrete myelin around the 
neurons (Piet, 2004).  Several different tumors of varying morbidities can form from astrocytes, 
and their malignant potential is graded on a four-tiered system.  More aggressive tumors will 
have (1) increased cellularity, meaning its cells will be more differentiated from normal tissue, 
(2) increased mitoses, or rapidly-dividing cells, (3) endothelial progression, or the growth of 
blood vessels within the tumor mass, and (4) necrosis, or the death of surrounding tissues 
(Collins, 2004).  GBM possesses all four characteristics, leading to a WHO Grade IV ranking, 
the most aggressive.    
 
Several treatment options are commonly pursued for treatment of GBM.  Treatment often 
begins with surgical resection.  In less aggressive tumors, surgical resection is often regarded 
as curative, whereas in the treatment of GBM, resection is only palliative.  Resection pursues 
several goals.  Surgery strives to balance the removal of as much tumor as possible with the 
maintenance of neurologic function.  Because GBM is especially infiltrative and often multifocal 
(Devita, 2001), it is often impossible to remove the entire tumor mass.  Consequently, in the 
case of GBM, resection cannot cure the disease, but does relieve symptoms through reduction 
of intracranial pressure and tumor burden.  Surgery often provides a modest increase in 
median survival time by a few months.   
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Radiation treatment can also provide palliative benefit to GBM patients.  However, the 
invasiveness of the disease again presents difficulties, as the radiation beam is focused on 
areas including both solid tumor tissue and the surrounding invasive tumor within normal tissue 
(DeVita, 2001).  Acute toxicities include nausea, vomiting and headache, while later reactions 
include neurologic deficits due to radiation-induced demyelination of neurons or capillary 
permeability changes (DeVita, 2001).  Learning capacity and abstraction ability can be 
impaired by radiation treatment. In severe cases, necrosis may occur. 
 
Chemotherapeutic agents are often used, as well.  The basic goal of chemotherapy treatment 
is to kill tumor cells with a sufficient specificity to minimize toxicity of normal cells.  Significantly, 
tumor cells generally undergo rapid cell division, whereas most normal cells in adults are 
senescent.  Because dividing cells must replicate their DNA, hindering DNA replication in 
theory serves as a desirable target for treatment.  Consequently, agents such as carmustine, 
temozolomide, and cisplatin, which damage DNA through various chemical processes, are 
often used (Rabik, 2006).  However, the specificity of these drugs is not absolute, as the 
tissues that still undergo cell division and growth, such as hair follicles, gastrointestinal 
epithelium, and reproductive organs, are adversely affected.  Moreover, the restrictiveness of 
the blood-brain barrier prevents many otherwise-promising agents, such as bleomycin, 
doxorubicin, cisplatin, and vincristine, from reaching tumor in effective amounts at levels that 
would not cause dose-limiting toxicities (DeVita, 2001).  Moreover, GBM tumors often evolve to 
become resistant to treatment with chemotherapeutic agents.  The effect of DNA alkylating 
agents, for instance, can be mitigated by alkyltransferases in tumor cells that repair the DNA 
damage, allowing the tumor cells to survive treatment (Rabik, 2006). 
 
While these standard treatments do provide benefit to GBM patients, their effects are modest.  
Combination radio- and chemo-therapy treatments improve median 50% survival times to 
approximately 55 weeks (DeVita, 2001). Because standard treatments provide patients with 
only modest benefit and substantial toxicity, it is necessary to explore other types of treatment 
strategies.  Drugs that target epigenetic processes are currently being explored in early phase 
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clinical trials and preliminary data suggests that several of these agents hold great promise for 
patients with cancer.   
 
All of the genetic information in a cell is encoded in its DNA, a long chemical strand composed 
of different nucleotides.  These nucleotides act as the chemical letters that spell out the genetic 
information.  Enzymes read this genetic information and transcribe into a messenger molecule, 
mRNA.  This mRNA molecule is then translated through other cellular machinery known as 
ribosomes into proteins. These proteins can then perform specific chemical functions, such as 
breaking down sugars for energy, sending or receiving signals, and building cellular structures 
(Cambell, 2002).  The individual genetic instructions (sequence) within the DNA that codes for 
a specific protein is known as a gene.  Genes themselves are divided into several parts.  The 
most important are the open reading frame that contains the information for the protein, and 
the promoter, a region usually immediately before the open reading frame.  Regulatory 
proteins can bind to the promoters of genes, and depending on the type of regulatory protein, 
they can induce or inhibit transcription of the gene. (Snyder, 2003) Thus a cell can control 
when proteins are produced through promoter regions. 
 
 
Figure 1.  Genetic mutations can cause changes in protein structure.  DNA replication 
errors and DNA-damaging agents, such as mutagenic chemicals and ultraviolet radiation, 
can change the base-pair sequence of genes.  When these genes are translated, the 
resulting proteins may have a mutated amino acid sequence, possibly resulting in different 
structures and functions. 
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Conventional genetic events occur when the base-pair sequence of a gene is modified, 
potentially changing the information encoded.  For instance, point mutations occur when a 
single nucleotide changed, perhaps due to the incorporation of an incorrect nucleotide during 
replication, or a chemical modification of the nucleotide due to UV irradiation or chemical 
mutagens.  Alternatively, frame-shift errors can insert or remove a few nucleotides, leading to 
an erroneous reading frame during translation.  Larger scale changes include deletions, 
duplications, or inversions of large sequences of nucleotides, or even chromosome 
translocations.  (Kramer, 2002).  These genetic modifications that affect the DNA code 
sequence can change the abundance and functionality of the proteins encoded by the gene.  If 
the genetic changes affect the coded portion of the gene, the protein encoded by the gene 
affected can be changed (mutated).  These changes can affect the protein’s ability to bind with 
its substrate or with other regulatory molecules, causing it to work incorrectly.  Alternatively, if 
the promoter region of the gene is changed, the protein can be produced under inappropriate 
circumstances (dysregulation), or over / under expressed.  
 
 
In contrast, epigenetic modifications do not change the base-pair sequence of a gene, and the 
proteins produced have the same sequences as before.  Rather, epigenetic modifications acts 
as a switch to turn genes on or off.  This switching mechanism occurs through the opening and 
closing of the DNA/protein superstructure referred to as chromatin (Jones, 2007).  DNA 
associates with proteins known as histones in an arrangement similar to spaghetti wrapped 
Figure 2.  Epigenetic modifications can silence genes.  By increasing the affinity of 
histones for the DNA strands, repressive epigenetic events can prevent the transcriptional 
enzymes from accessing the DNA strand.  Transcription of the gene is then epigenetically 
silenced. 
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around a meatball.  This provides the cell with an additional means of organizing its genetic 
program and provide an important layer allowing for tight control of gene expression regulation.   
 
 
By default, chromatin structure is maintained in a compact/closed fashion that is not 
permissive to gene transcription.  Specific covalent modifications to DNA and histones can 
alter the affinity a histone protein has for DNA and cause chromatin to assume a more open 
structure.  Open chromatin allows chromatin remodeling complexes to further modify the 
protein/DNA structure leading to further “relaxation” of key promoter regions that, in turn, 
become more permissive to the docking of transcriptional machinery and expression of the 
protein of interest (Sif, 2004). The modulation of chromatin binding stems from the concerted 
effects of a two-step process.  First, covalent modifications to the histones can change their 
affinity for the DNA.  Second, chromatin remodeling enzymes change the superstructure of the 
chromatin according to the binding dictated by histone modifications. For instance, if histones 
bind DNA loosely, remodellers unwind DNA from histones, allowing transcription enzymes to 
Figure 3.  SWI/SNF modifies the chromatin superstructure.  Chromatin remodeling 
complexes such as SWI/SNF can modify the chromatin superstructure, either converting 
condense heterochromatin to relaxed euchromatin (as shown) or reverting the relaxed 
euchromatin back to condensed heterochromatin.  When the genes are condensed into 
heterochromatin, transcription is inhibited, but relaxed euchromatin allows transcription. 
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read the gene.  Alternatively, if histone/DNA modifications result in a stronger affinity for DNA 
(DNA methylation, histone deacetylation, histone hypomethylation), chromatin remodelers will 
work oppositely, winding the DNA back up, and preventing transcription (Roberts, 2004).   
 
 
The first step of altering DNA-histone affinities is affected by numerous modifications to 
proteins associated with the DNA.  These changes are primarily achieved through covalent 
modification of histones.  The N-terminal tails of the histone proteins serve as substrates for 
numerous difference chemical modifications, including acetylation, methylation, 
phosphorylation, ubiquitination, sumoylation, and deimination, but the best characterized are 
acetylation and methylation (Kouzarides, 2007).  Acetylation of lysine amino acids in the 
histone tails almost universally leads to transcriptional activation.  The acetyl group neutralizes 
the lysines’ positive charge, reducing its affinity for the negatively-charged DNA strand.  Thus, 
Figure 4. Histone-modifying enzymes modulate histone-DNA binding affinities.  
Histone Acetyltransferases (HATs) catalyze acetylation of N-terminal tails of histone 
proteins generally facilitates loose histone0DNA binding, which allows chromatin 
remodellers to reconfigure the chromatin superstructure and allow transcription. Histone 
Deacetyltransferases (HDACs) reverse this process.  Certain specific histone 
methyltranserases such as PRMT5 facilitate loose histone-DNA binding and allow 
transcription, while other specific histone methyltransferases, such as PRMT6, facilitate 
tight histone-DNA binding and inhibit transcription. 
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increasing the acetylation of histones causes a loose histone-DNA binding affinity, allowing 
chromatin remodellers to reshape the DNA, facilitating transcription.  Histone tail acetylation is 
controlled by the effects of two opposing classes of enzymes, histone acetyltransferases 
(HATs) and histone deacetyltransferases (HDACs), and changes in the relative activities of 
these enzymes can affect gene transcription (Bolden, 2006).   
 
Another common modification to histone tails is methylation, which can occur on lysine and 
arginine residues.  Methylation of lysine residues is caused by lysine methylases and reversed 
by lysine demethylases, while arnigines are methylated by argnine methylases.  There are no 
known enzymes with arginine demethylating activity, although the methyl-arginine residue can 
be irreversibly degraded through deiminases (Kouzarides, 2007).  The effect of these 
modifications is site-specific, as methylation on certain residues activates transcription, while 
other residues leads to gene silencing, and it is unclear exactly how these differing effects are 
mediated.  For example, the protein arginine methyltransferase 5 enzyme acts to silence target 
genes by transferring a methyl group to the 8th arginine residue on histone 3 (H3 R8) and the 
third arginine residue on histone 4 (H4 R3) (Pal, 2004).   
 
Epigenetic dysregulation of important genes may play a crucial role in cancer.  Normal cells 
express tumor-suppressor genes that check for defects in the cell and respond, often by 
preventing cell reproduction via induction of cell death or cell cycle arrest.  Work in numerous 
tumors has found that tumor-suppressor genes are silenced genetic and epigenetic 
mechanisms.  Genome-wide screens in GBM cell lines has shown that numerous genes are 
silenced epigenetically due to DNA methylation, including BIK, a pro-apoptotic protein (Kim, 
2006).  Treatment of GBM lines with SAHA, a histone deacetylase inhibitor, resulted in 
induction of p21WAF1 and P27KIP1, two genes that regulate cell cycle progression (Yin, 
2007).  Pal et al. has recently shown that PRMT5 associates with the chromatin remodeling 
complex SWI/SNF to turn off the tumor suppressor genes ST7 and NM23 (Pal, 2004).  Our lab, 
in collaboration with Dr. Said Sif, has recently shown that PRMT5 works in concert with 
HDAC2 to repress ST7 expression in mantle cell lymphoma (Unpublished data).  Thus, it is 
becoming clear that enzymes that covalently alter the chemical nature of chromatin are 
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capable of altering the cells threshold for transformation.  Thus, it stands to reason that these 
enzymes, if dysregulated in human cancer, may serve as effective targets for anti-neoplastic 
therapy.   
 
Figure 5. Epigenetic repression of anticancer genes and rationale for targeting HDAC 
and PRMT5 co-repressor enzymes in lymphoma. (A) Both activating and repressive 
SWI/SNF complexes co-exist in a the cellular proteome. Hypoacetylation of histones H3 and 
H4 promote PRMT5-driven methylation of arginine residues resulting in condensed 
nucleosomal structure and repression of target tumor suppressor genes. (B) Following 
treatment with drugs that inhibit HDAC (HDAC-I) and PRMT5 (PRMT5-I) activity, HAT 
enzymes are able to covalently modify N-terminal lysine residues on H3 and H4 histone 
subunits resulting in loss of ability for PRMT5 to maintain methylation of its target AA residues. 
Consequently, repressive SWI/SNF complex affinity for the modified chromatin is lost and 
these complexes become displaced. HAT and type I histone methyltransferases act to further 
modify nucleosome conformation. (C) Differential recruitment of activating SWI/SNF 
complexes remodel chromatin allowing for transcriptional machinery to gain access to 
regulatory regions on genomic DNA and for gene transcription of tumor suppressor genes to 
proceed.   
 
HYPOTHESIS:  A critical event that occurs during cellular transformation involves silencing of 
key cellular genes that regulate cell growth and survival. Enzymes such as PRMT5, HDACs 
and DNMT, have been shown to associate with repressive SWI/SNF complexes that directly 
target and silence several important regulatory genes. These three enzymes modify epigenetic 
events and act in concert to repress transcription of tumor suppressor genes like ST7. 
Inhibition of these repressive enzyme activities will reverse silencing of tumor 
suppressor genes, mitigate cell cycle defects, reduce growth rate, and lower the 
apoptosis threshold of transformed GBM cells.  
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Materials and Methods 
Cell culture:U87MG, U251MG,A172, U118, U1242, U118, and M059K cell lines were kindly 
donated by James Van Brocklyn (Ohio State University).  Gli36 cell line was kindly donated by 
Antonia Chiocca (Ohio State University).  U87MG, U251MG, A172, U118, U1242, U118, and 
M059K lines were grown in Eagle’s minimal essential medium (Gibco) with 10% fetal bovine 
serum (Gibco), non-essential amino acids, sodium pyruvate, penicillin (100 U/ml) streptomycin 
(100 ug/ml), and amphotericin B (0.25 ug/ml) (Gibco). Gli36 cells were grown in RPMI 1640 
medium with 10% fetal bovine serum, penicillin (100 U/ml) streptomycin (100 ug/ml), and 
amphotericin B (0.25 ug/ml) (Gibco).  Cells were cultured at 37°C in 95% air/5% CO2. 
 
Drugs and reagents:  HDACi 42 was obtained from Ching-Shih Chen (Ohio State University 
and stored in 10 mM stock solutions in DMSO at -80°C.  Cisplatin was purchased from Bristol 
Myers-Squibb and was stored in 3.3 mM in PBS at -80°C.  Depsipeptide was obtained from 
Fusijawa Pharmaceutical and was stored as a stock solution at 5 uM in acetonitrile at 4°C.   
 
Western blotting: Samples were washed twice with cold PBS, before extraction with RIPA 
lysis buffer (150 mM NaCl, 1.0% Triton X-100, 1% deoxycholic acid, 0.1% SDS, 5mM EDTA 
and 10 mM Tris, pH 7.4).  Three times, samples were vortexed and incubated on ice for 10 
minutes.  Samples were then centrifuged for 10 minutes at 4°C at 16,000g.  Supernatants 
were the quantified using BCA assay with BSA standards.  Samples were eluted in 6x Laemmli 
Buffer, and 30 ug of total protein was loaded in 10-12% SDS-PAGE gels, run at 90V for 
approximately 2 hours, and transferred to nitrocellulose membranes.  Samples were blocked 
with 5% milk in 0.5% Tween 20-TBS.  Membrane preparations were incubated overnight at 
4°C the appropriate primary antibody, then rinsed in 0.5% Tween 20-TBS, and incubated at 
4°C with the appropriate seconday antibody. Blots were visualized using the SuperSignal West 
Pico Chemiluniescent Substrate or SuperSignal West Femto Maximum Sensitivity Substrate 
(both Pierce), and exposing to Hyblot CL autoradiography film (Denville Scientific) 
Antibodies used were rabbit-anti-PRMT5 (kindly donated by Said Sif, Ohio State University) at 
1:500 in 5% milk-0.5% Tween 20-TBS, rabbit-anti-ST7 (kindly donated by Said Sif, Ohio State 
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University) at 1:400 in 5% milk-0.5% Tween 20-TBS, goat-anti-actin polyclonal IgG (Santa 
Cruz Biotechnologies) at 1:1000 in 5% milk-0.5% Tween 20-TBS, donket-anti-goat-HRP IgG 
(Santa Cruz Biotechnologies) at 1:3000 in 5% milk-0.5% Tween 20-TBS, and anti-rabbit-HRP 
F(ab’)2 fragment from donkey (GE Healthcare, NA9340) at  1:3000 in 5% milk-0.5% Tween 
20-TBS. 
RNA interference: A DNA fragment with sequence as described by Pal et al (2004) was 
obtained from Said Sif.  This DNA fragment was used as a template for an siRNA 
oligonucleotide targeting PRMT5 mRNA using the Ambion Silencer siRNA Construction Kit, 
using manufacturer’s instructions.  siRNA was quantified using the NanoDrop ND-1000, 
aliquoted in TE buffer, and stored at -20°C.  Negative control siRNA sequence with no 
homology to any known open reading frame was obtained from MWG (Non-specific control 
dublex, 47% GC content). 
siRNA transfection experiments were performed by seeding 6-well plates with either 5x104 
U251MG cells or 1.5x105 U87MG cells in normal growth media, without antibiotics.  Cells were 
grown until 30-50% confluent, then, siRNA at final concentrations from 2.5 to 40 nM was 
transfected using the Lipofectamine 2000 (Invitrogen) protocol, scaled to 6 well plates. 
 
Flow cytometry: Cell cycle analysis was performed by first mildly trypsinizing cells.   
For cell cycle analysis, Gli36 cells were stained with propidium iodide according to 
manufacturer’s protocols, and flow cytometry was performed as described in Roychowdhury et 
al (2004).   
For apoptosis staining, U87MG, Gli 36, and U251MG cells mildly trypsinized, washed twice in 
cold PBS, resuspended in Annexin Bindng Buffer (BD Pharmingen) at 1x106 cells/ml.  To 
1x105 resuspended cells, 5 ul of Annexin V-FITC (BD Pharmingen) and 5 ul of TOPRO 3 
(Molecular Probes) were added, and the cells were incubated at room temperature protected 
from light for 15 minutes.  Flow cytometry was performed according to manufacturer’s 
protocols using BD FACScalibur (BD Pharmingen).  The data were analyzed using WinMDI, 
using forward- and side-scatter to gate desired cell population, and plotting population’s FL-4 
fluorescence versus FL-1 fluorescence.  Double-negative cells were regarded as living, 
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annexin-positive cells were regarded as apoptotic, and double-positive cells were regarded as 
dead. 
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Results and Discussion 
HDAC inhibitors induce cell cycle arrest.   
 
Figure 6. HDAC inhibitors induce cell cycle arrest. Cells were grown to 50% conflucence 
and cultured in media containing varying concentrations of HDAC inhibitors. Cells were 
harvested at 24 and 48 hrs and stained with the nuclear dye propidium iodide. DNA content 
was then evaluated via flow cytometry.  Cell cycle arrest was induced by depsipeptide at 24 
hours, and DNA fragmentation was observed at 48 hours. 
Gli36 cells were treated with either depsipeptide, a cyclical peptide inhibitor of HDAC currently 
undergoing Phase II trials or an acetonitrile vehicle control. As cells progress through the cell 
cycle, a series of steps required to divide, they must replicate all of their DNA.  Measurement 
of the relative amounts of DNA within a cell provides an accepted measure of where cells are 
in the cell cycle.  This is done through propidium iodide staining and flow cytometry.  Cells are 
treated with with antibodies or dyes that adhere to a structure of interest.  Antibodies are 
conjugated to fluorochromes, and the dyes often are themselves fluorochromes, so they emit a 
light of a given wavelength when undergoing excitation under a laser.  By running prepared 
cells through a flow cytometer, the relative abundance of fluorescence within those cells can 
be measured.  Propidium iodide is a stain that intercalates between the base pairs of DNA, so 
increased DNA content in a cell causes increased fluorescence.  This assay produced a 
histogram output with an absolute cell count plotted against propidium fluorescence, or relative 
DNA content. 
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Within the 24 hour data, a comparison between the Depsipeptide-treated cells and the control 
indicates cell cycle arrest is occurring at the G2/M checkpoint (the point with the greatest 
amount of DNA).  The peak at 200 fluorescence units represents cells in G1 phase, which 
have one copy of each DNA strand.  As cells synthesize more DNA, the fluorescence 
increases, until a second peak is reached at 400 units, when the cells have two copies.  In all 
of the depsipeptide-treated samples at 24 hours, a second peak accumulates at 400 units, 
while the second peak with duplicated DNA does not accumulate in the control.  Consequently, 
we can conclude that cell cycle arrest is induced by depsipeptide at the G2/M checkpoint at 24 
hours.  In other work with mantle cell lymphoma cells, we have shown that HDACi causes 
induction / re expression of several cell cycle inhibitors that are found to be shut down in 
transformed cells.   
 
At 48 hours, in depsipeptide-treated cells, fluorescence is observed below 200 units, indicating 
some cells have hypodiploid levels of DNA.  This is indicative of apoptosis, the process by 
which cells undergo programmed cell death, as apoptotic cells degrade their DNA, resulting in 
cells with less than normal levels of intact genomic DNA.  This phenomenon did not occur at 
48 hours with only acetonitrile control, suggesting apoptosis was induced by the depsipeptide 
compound.  Because an HDAC inhibitor appeared to induce apoptosis from this assay, we 
decided to test for this specifically, using a novel HDAC inhibitor, HDACi 42 developed at Ohio 
State University by Ching-Shih Chen, that has been previously shown to have anticancer 
properties in glioblastoma multiforme cell lines (Chen, 2005).  Death can occur via apoptosis or 
by necrosis. Propidium iodide is not capable of distinguishing between the two mechanisms of 
cell death, therefore we performed a separate set of experiments looking for the detection of 
annexin V on the surface of cells treated with HDAC-I.  
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HDAC inhibitors induce apoptosis.   
 
Two cell lines, U87 and U251, were grown in increasing concentrations of HDACi42.  At 72 
hours, apoptosis was measured by flow cytometry, staining cells with a fluorochrome-
conjugated antibody, Annexin V-FITC, and Topro-3, a dye that intercalates DNA strands.  
Annexin V binds phophatidylserine compounds that typically are found on the inside of cell 
membranes, but as the cell undergoes apoptosis, they accumulate on the outside.  Thus, cells 
that exhibit Annexin V positivity are beginning apoptosis.  Cells that have died by necrosis or 
apoptosis have permeabilized membranes, allowing Topro 3 to enter the cell and bind their 
DNA.  Thus, cells that are positive for both Annexin V and Topro 3 are completely dead. 
Figure 7.  HDAC inhibitors induce apoptosis.  Two GBM cell lines, U87 and U251, were 
grown in the presence of varying concentrations of an HDAC inhibitor, HDACi42.  After 72 
hours, apoptosis was assayed through flow cytometry, staining for Annexin V and TOPRO-3 
(a DNA dye like propidium iodide).  Double-negative cell events were interpreted as 
surviving cells.  Apoptosis increased in a dose-dependent fashion in both cell lines. 
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HD42 and Cisplatin at 72 hours
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Data was analyzed, and the percentage of cells that were both Annexin V and Topro 3 
negative--and therefore had not initiated apoptosis—were quantified.  
 
Dose-dependent induction of apoptosis was observed in both cell lines.  Increasing 
concentrations of HDACi42 induced increasing levels of apoptosis.  Significantly, similar levels 
of apoptosis were not observed in each cell line.  Different continuous cell lines were isolated 
from different patients.  These different cell lines may possess different genetic and epigenetic 
irregularities, and these disparities may translate into different sensitivities to drugs.  More 
mechanistic work to characterize the molecular differences between the cell lines is needed. 
 
HDAC inhibitors reduce apoptotic threshold for standard chemotherapeutics 
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Gli 36 and U251 MG cells were grown in sublethal concentrations of HDACi42 (1 uM) and 
cisplatin (3.3 uM), a common chemotherapeutic agent that damages DNA.  Apoptosis was 
again measured using flow cytometry, and staining with Annexin V-FITC and Topro-3.  In both 
cell lines, addition of a single compound induced apoptosis in a portion of the cell population.  
At 72 hours, cisplatin alone reduced cell survival from 90% to 65% in U251 MG cells, and from 
93% to 75% in Gli 36 cells. HDACi42 alone reduced cell survival from 90% to 55% in U251 MG 
cells, and from 93% to 68% in Gli 36 cells.  However, the addition of both compounds together 
led to a greater than additive effect, as cell survival in U251 MG cells was reduced to 5%, and 
Gli 36 survival was reduced to 25%.  
 
These results indicate that HDACi42 can sensitize cells to chemotherapeutics, due to several 
possibilities.  First, the effect could be a non-specific, genome-wide result, as HDAC inhibitors 
could open up chromatin structures, making DNA strands more accessible to cisplatin-induced 
DNA lesions.  Alternatively, the epigenetic effect of HDACi42 could derepress important tumor-
suppressor genes.  Such genes could affect numerous cell signaling pathways, rendering the 
cells more amenable to apoptosis.  Importantly, these explanations are not mutually exclusive.  
However, to elucidate the mechanism of the second possibility, genome-wide screens would 
need to be performed to find upregulated genes, and these genes would need to be 
individually silenced to confirm their necessity to the process. 
 
We concluded that HDAC enzymes play an important role in the regulation of apoptosis and 
cell cycle in glioblastoma cells.  Because HDAC enzymes have been shown to associate with 
other enzymes with repressor activity (DNMT and PRMT5) to target and silence important 
gene regulatory gene products, we next sought to investigate the role of histone methylation 
via PRMT5 in GBM tumors. 
Figure 8.  Reduction of apoptotic threshold by HDAC inhibitors for 
chemotherapeutics.  Two GBM cell lines, Gli36 and U251, were grown in the presence of 
an HDAC inhibitor, HDACi42 at 1 uM, and the chemotherapeutic agent, cisplatin, at 3.3 uM.  
After 72 hours, apoptosis was assayed through flow cytometry, staining for Annexin V and 
TOPRO-3.  Low concentrations of HDAC inhibitors sensitize GBM lines to standard 
chemotherapeutic agents. 
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PRMT5 over expression and tumor suppressor gene silencing in GBM lines.  Total cell 
protein lysates were prepared from GBM and control cells with RIPA buffer.  30ug total protein 
was subjected to PAGE and western blots were performed with antisera specific for PRMT5 
and a direct target gene of PRMT5, ST7.  PRMT5 is ubiquitously over expressed among GBM 
cell lines and the tumor suppressor gene ST7 is silenced. Pal et al (2003) have shown that the 
tumor suppressor genes ST7 and NM23 are directly targeted and silenced by SWI/SNF 
complexes that contain PRMT5, HDAC and DNMT1.  Chromatin immuno precipitation (ChIP) 
experiments have previously demonstrated ST7 to be directly repressed by PRMT5-associated 
SWI/SNF complexes (Pal et al, 2003). Resting B cells are negative control for PRMT5. Jijoye 
and LCLMS are two EBV+ transformed B cell lines that serve as the positive control for 
PRMT5.   
 
Western blots need appropriate loading controls, to ensure an equal amount of protein is 
loaded in each well and that different levels of protein as indicated on the blot actually 
correspond to differing levels in the cells.  Actin was used as this control; due to its role as a 
key member of the  cytoskeleton, it is highly, universally expressed, and is affected minimally 
by treatment, so actin levels are generally proportional with protein levels overall. 
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All six GBM lines (U87 MG, U118 MG, U251 MG, U373 MG, U1242 MG, and A172) expressed 
abundant levels of PRMT5, and importantly, within these lines, no expression of ST7, a tumor-
supressor gene silenced by PRMT5, was observed.  Resting B-cells, which were previously 
known to express minimal levels of PMRT5 and express abundant ST7, demonstrated that the 
anti-PRMT5 antibody did not bind aspecifically, and the ST7 antibody was functional.  Jijoye 
and LCL 100, two B-cell tumor lines previously known to express PRMT5 and not ST7, 
demonstrated the PRMT5 antibody worked correctly.  We concluded that PRMT5 is 
overexpressed in all GBM lines observed, and that this expression is correlated with ST7 
silencing, although we have not yet demonstrated silencing of ST7 is caused by 
overexpression of PRMT5.  We will be repeating ChIP experiments in GBM lines to prove that 
ST7 is directly targeted.   
 
We next sought to silence PRMT5 using an siRNA oligonucleotide.  Silencing PRMT5 with 
SiRNA.  We have generated antisense and SiRNA reagents for evaluating the role PRMT5 
plays alone and in concert with HDAC and DNMT enzymes with respect to tumor suppressor 
gene expression and cellular transformation.   
Figure 9. PRMT5 expression in a panel of glioblastoma multiforme lines.  RIPA cell 
lysates of six GBM lines (U87, U118, U251, U373, U1242, and A172), as well as resting B 
cells, Jijoyre cells, and LCL MS cells, were made.  An SDS-PAGE gel was run with 30 ug of 
protein in each well.  Samples were probed for PRMT5, ST7, and actin (as a loading 
control).  Actin indicated the samples were loaded equally, the resting B cells indicated the 
ST7 antibody worked correctly, and the Jijoye and LCL MS cell lines indicated the PRMT5 
antibody worked correctly.  PRMT5 was universally expressed in all GBM lines tested, and 
ST7 was universally silenced. 
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U251 MG cells were treated with increasing concentrations of an siRNA antisense to PRMT5 
mRNA.  siRNA strands a small, double-stranded RNA sequences, which bind to Dicer, a 
riboendonuclease that cleaves the siRNA into single-strands.  These single-stranded RNA’s 
bind with another endonuclease, forming the RISC complex.  The single-strand RNA antisense 
to the mRNA of interest binds to that mRNA, and the endonuclease in the RISC complex 
cleaves the mRNA.  Consequently, genes can be silenced experimentally. 
 
After the U251 MG cells were grown for one week after siRNA introduction, cells were lysed 
and run on a Western blot, probing for PRMT5 levels.  Although the actin control bands at 
lower siRNA concentrations are not evident—probably due to a transfer error, loading bands at 
higher concentrations are evident.  Consequently, we can conclude that the reduced 
expression of PRMT5 at 10 nM is due to silencing by siRNA.   
 
Scramble siRNA was used as a control.  Its sequence has no homology to any known gene, so 
it cannot, as far as is known, silence genes through a RISC complex.  The abundance of 
PRMT5 in cells treated with scramble siRNA indicates that the mere presence of the siRNA 
chemically cannot knockdown PRMT5 levels; rather, a specific sequence antisense to PRMT5 
is necessary.  The three lanes on the right act as controls for antibody function in the Western 
blot and indicate that the PRMT5 antibody worked functionally and specifically. 
 
Figure 10. siRNA knockdown of PRMT5 in U251 MG cells.  U251 MG cells were 
transfected with increasing concentrations of siRNA specific to the PRMT5 sequence, and 
increasing concentrations of a non-specific siRNA (Scr siRNA).  After one week of growth, 
cells were lysed using RIPA buffer, and run in a SDS-PAGE gel, with 30 ug protein per 
well.  Each sample was probed for PRMT5 and actin, as a loading control.  Observed 
actin loading is inconsistent, possibly due to a transfer error, but loading was adequate at 
higher concentrations of pRMT5 siRNA, indicating PRMT5 knockdown occurred.  
Expression of PRMT5 in presence of non-specific siRNA indicated the sequence-
specificity of the siRNA was necessary for knockdown.  B cell, Jijoye, and LCL lysates 
indicated antibodies worked properly for Western blot. 
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Conclusions 
We have concluded that HDAC does play an important role in the biology of glioblastoma 
multiforme. Moreover, mitigating its effects via chemical HDAC inhibitors such as HDACi42 
and depsipeptide induces cell cycle arrest and apoptosis, while making cells more amenable to 
traditional chemotherapeutic treatments.  We are currently working on clarifying the 
mechanism(s) that become operable during HDACi-induced apoptosis.  
 
PRMT5 has been shown to be expressed in all GBM lines investigated, and correlates with 
ST7 silencing.  Moreover, PRMT5 can be silenced using specific siRNA compounds. More 
recent work in our lab has demonstrated that PRMT5 cooperates with HDAC enzymes to 
silence at least 5 tumor suppressor genes including 3 in the retinoblastoma family (Rb, p105, 
p107 and p110).  This will have great implications if we determine that ST7 and Rb family 
proteins are repressed by PRMT5 assisted processes because development of inhibitors to 
PRMT5 may become active anti neoplastic agents.  We are currently exploring a wide 
screening of multiple natural products and small molecules to discover candidate compounds 
with PRMT5-inhibitory activity.    
 
Our continued work will focus on several specific aspects of the epigenetics of GBM.  First, we 
will investigate the mechanism of HDAC and its inhibition in the cells, testing for the overall 
levels of difference HDAC enzymes, such as HDAC2, and for their association with Swi/SNF 
complexes in GBM.  Second, we will use Western blots to measure specific histone acetylation 
and nonspecific protein acetylation under HDACi treatment, and find which cellular phenotypic 
changes correlate with specific histone acetylation.   
 
Third, we will investigate the various phenotypic changes associated with inhibition of PRMT5, 
and whether its silencing has any effect on proliferation, apoptosis.  Moreover, we will 
investigate whether PRMT5 acts on ST7 directly, as in B-cell tumors, through chromatin 
mmunoprecipitation assays. 
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Fourth, we will investigate whether other epigenetic processes such as DNA methylation are 
important in GBM and if enzymes with DNA methylation activity are associating with PRMT5 
and HDAC-containing SWI/SNF complexes.  
 
Finally, we will investigate whether combination therapy targeting multiple epigenetic 
processes can induce a synergistic response in GBM cells, serving as an effective treatment 
using minimal doses of all agents. 
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